Transdermal Platform Bypasses 500-Dalton Rule, Aims at Tumor Acidity
Dyve Biosciences says its topical platform absorbs in minutes and delivers molecules past 500 daltons. Its lead program, DV800, targets acidic tumor microenvironments with Moffitt Cancer Center.